有色人种晚期皮肤及原发不明黑色素瘤的分子特征
该回顾性队列分析676例接受MSK-IMPACT测序的晚期皮肤及原发不明黑色素瘤患者,比较自报有色人种与非西班牙裔白人。自报有色人种BRAF V600E突变占43%,全野生型肿瘤更多(14% vs 4%,P=.010),浅肤色者中位肿瘤突变负荷高于中/深肤色者(15.8 vs 2.6,P<.0001)。
要点
- 自报有色人种晚期黑色素瘤中全野生型肿瘤比例高于非西班牙裔白人(14% vs 4%)。
- 浅肤色患者中位肿瘤突变负荷高于中/深肤色患者(15.8 vs 2.6)。
- 肤色与遗传推断祖源不能稳定预测基因组特征,需扩大样本验证。
核心结论
- 自报有色人种的皮肤及原发不明黑色素瘤中位肿瘤突变负荷更低、更常见全野生型肿瘤,提示发病机制存在差异。
- 需要更大规模研究验证上述发现。
研究设计与样本
- 回顾性便利队列,纳入676例接受临床所需MSK-IMPACT多基因测序的晚期皮肤及原发不明黑色素瘤患者。
- 自报有色人种定义为非白人种族和/或西班牙裔,另按遗传推断祖源与Monk量表肤色分析。
主要发现
- 自报有色人种(n=35)中BRAF V600E突变占43%。
- 与非西班牙裔白人(n=641)相比,自报有色人种全野生型(未知驱动)肿瘤更多(14% vs 4%;P=.010)。
- 自报有色人种中肤色与推断祖源仅中度重叠,且不能一致预测基因组特征。
- 浅肤色患者(n=185)中位肿瘤突变负荷高于中/深肤色患者(n=8)(15.8 vs 2.6;P<.0001)。
临床怎么用
- 对有色人种晚期黑色素瘤患者应重视全野生型可能,测序解读需结合种族与肤色背景。
- 肤色与祖源不能替代分子检测,治疗方案选择仍应依据测序结果。
局限性
- 肤色评估仅覆盖部分患者(n=193)。
- 分子检测优先送检BRAF野生型患者,BRAF突变率可能被低估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cutaneous melanoma is rare in patients of color (POC), and the genomics are not well understood. OBJECTIVE: To describe mitogen-activated protein kinase drivers and tumor mutational burden of cutaneous and unknown primary melanoma in POC and compare them with non-Hispanic White patients. METHODS: We analyzed a retrospective convenience cohort of 676 patients with advanced cutaneous and unknown primary melanoma undergoing clinically warranted multigene sequencing with Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets. Self-identified (self-ID) POC were defined as non-White race and/or Hispanic ethnicity; this cohort was also analyzed by genetically inferred ancestry and skin tone using the Monk scale. RESULTS: Self-ID POC (n = 35) had frequent B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E mutations (43%) and, compared with non-Hispanic White (N = 641) patients, more "pan-wild-type" tumors of unknown driver (14% vs 4%; P = .010). Among self-ID POC, skin tone and inferred ancestry showed moderate overlap, but did not consistently predict genomic features. Median tumor mutational burden was higher among patients with light (N = 185) than among patients with medium or dark (N = 8) skin tone (15.8 vs 2.6; P < .0001). LIMITATIONS: Skin tone assessments were only available for a subset of patients (N = 193). BRAF mutations are underestimated given molecular testing preferentially sent in patients with BRAF wild-type disease. CONCLUSION: Cutaneous and unknown primary melanomas in self-ID POC had lower median tumor mutational burden and were more likely to be pan-wild-type, reflecting differences in pathogenesis. Larger-scale studies are needed to validate these findings.
引用
- Ross JS, Weir VR, Lavin L, et al. Molecular alterations in patients of color with advanced cutaneous and unknown primary melanomas. J Am Acad Dermatol. 2026. PMID: 42600747. doi:10.1016/j.jaad.2026.08.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。